Short communication
In patients with pulmonary hypertension caused by chronic lung disease, iron deficiency is linked to more severe pulmonary vascular disease.
Author(s): Tatiana Williams*
Group 3 Pulmonary Hypertension (PH) is the second most frequent type of Pulmonary Hypertension (PH), although it has the greatest mortality rate of all PH illnesses. Group 3 PH patients have few therapy options; while inhaled treprostinil improves exercise capacity, patients nevertheless have a high morbidity and mortality rate. As a result, more research into the pathophysiologic findings of group 3 PH is needed, in the hopes of identifying possible treatment targets to battle the high symptom burden and poor outcomes experienced by these individuals. Parenteral iron treatment has been proven to enhance exercise capacity, New York Heart Association functional class, and patient wellbeing in chronic left heart failure, where iron deficiency is frequent and deleterious.The significance of iron in the natural history of Pulmonary Arterial Hypertension is gaining popularity (PAH). The av.. Read More»
DOI:
10.37532/pulclr.2022.3(1).1-2
+447723598358
